[Risk of methemoglobinemia after Emla application in premature infants].
D000779:Anesthetics, Local / Q000009:adverse effects*; D004338:Drug Combinations; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008012:Lidocaine / Q000009:adverse effects*; D000077442:Lidocaine, Prilocaine Drug Combination; D008708:Methemoglobinemia / Q000139:chemically induced*; D009824:Ointments; D011318:Prilocaine / Q000009:adverse effects*; D012306:Risk
D000779:Anesthetics, Local; D004338:Drug Combinations; D000077442:Lidocaine, Prilocaine Drug Combination; D009824:Ointments; D011318:Prilocaine; D008012:Lidocaine
Risque de méthémoglobinémie après application d'Emla chez les prématurés.